Medline (NASDAQ:MDLN) Price Target Raised to $60.00

Medline (NASDAQ:MDLN) had its target price hoisted by Citigroup from $48.00 to $60.00 in a research note issued to investors on Thursday,Benzinga reports. Citigroup currently has a buy rating on the stock.

A number of other research analysts also recently issued reports on MDLN. William Blair assumed coverage on shares of Medline in a research note on Monday, January 12th. They issued an “outperform” rating for the company. Bank of America initiated coverage on shares of Medline in a report on Monday, January 12th. They issued a “buy” rating and a $50.00 price objective on the stock. Mizuho assumed coverage on shares of Medline in a research report on Monday, January 12th. They set an “outperform” rating and a $48.00 price objective for the company. Robert W. Baird started coverage on Medline in a report on Monday, January 12th. They issued an “outperform” rating and a $48.00 target price on the stock. Finally, Evercore reaffirmed an “outperform” rating and set a $55.00 price target on shares of Medline in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.35.

Medline Trading Down 2.8%

Shares of NASDAQ MDLN opened at $47.51 on Thursday. The business’s 50-day moving average is $44.52. Medline has a 1-year low of $34.89 and a 1-year high of $50.88.

Medline (NASDAQ:MDLN) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.25). The firm had revenue of $7.79 billion during the quarter, compared to analyst estimates of $7.52 billion. Medline’s revenue was up 14.8% on a year-over-year basis.

Insider Buying and Selling at Medline

In related news, Director Andrew J. Mills purchased 2,586,206 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the transaction, the director directly owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the transaction, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. This represents a 55.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Carlyle Group Inc. acquired a new stake in Medline in the fourth quarter valued at about $9,042,728,000. H&F Corporate Investors X Ltd. purchased a new position in shares of Medline during the 4th quarter worth approximately $4,179,591,000. Vanguard Group Inc. acquired a new stake in shares of Medline in the 4th quarter valued at approximately $793,278,000. Morgan Stanley purchased a new stake in shares of Medline in the fourth quarter valued at approximately $636,807,000. Finally, Capital Research Global Investors acquired a new position in Medline during the fourth quarter worth $620,937,000.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Citigroup raised its price target to $60 and kept a “buy” rating — a ~26.6% upside from the recent price, highlighting conviction after the quarter. Citigroup Raise
• Positive Sentiment: UBS increased its target to $57 and maintained a “buy” rating — ~20.2% upside — reflecting upgraded forecasts post-Q4. UBS Raise
• Positive Sentiment: BMO lifted its target to $54 and set an “outperform” rating (~13.9% upside), joining other brokers in boosting estimates after the quarter. BMO Raise
• Positive Sentiment: RBC raised its target to $53 with an “outperform” call (~11.8% upside), another vote of confidence from the street. RBC Raise
• Neutral Sentiment: Analysts broadly boosted forecasts after Q4 results; summary coverage aggregates the upgrades and modeling adjustments. Analysts Boost Forecasts
• Neutral Sentiment: Medline’s Q4 earnings call highlighted record sales and strategic innovations — supportive for revenue trajectory but mixed vs. EPS expectations. Earnings Call Highlights
• Neutral Sentiment: Full earnings call transcript is available for investors who want detail on guidance, margin commentary and management tone. Earnings Transcript
• Neutral Sentiment: Wells Fargo raised its target slightly to $47 but kept an “equal weight” rating — effectively neutral near-term guidance from this shop. Wells Fargo Note
• Negative Sentiment: Shares gapped down after what coverage labels a weak earnings print (EPS miss despite a revenue beat), which prompted the initial selloff. Shares Gap Down
• Negative Sentiment: As Medline transitions to public markets, the IPO/ESOP disclosures and management’s growth guidance drew public scrutiny — a source of near-term uncertainty for investors. IPO Scrutiny

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.